

# Nancy L Bartlett

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1662737/publications.pdf>

Version: 2024-02-01

369  
papers

29,635  
citations

9786

73  
h-index

5539

163  
g-index

375  
all docs

375  
docs citations

375  
times ranked

20724  
citing authors

#	ARTICLE	IF	CITATIONS
1	Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. <i>Journal of Clinical Oncology</i> , 2023, 41, 336-342.	1.6	9
2	Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. <i>Blood</i> , 2022, 139, 1147-1159.	1.4	17
3	Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2022, 139, 1999-2010.	1.4	17
4	Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey. <i>Blood Advances</i> , 2022, 6, 2745-2756.	5.2	3
5	Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 481-491.	1.6	160
6	Stem cell transplant for lymphoma - never too late?. <i>Haematologica</i> , 2022, , .	3.5	0
7	COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience. <i>Leukemia and Lymphoma</i> , 2022, 63, 1723-1727.	1.3	1
8	Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 821-833.	1.3	8
9	Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e435-e442.	0.4	6
10	Alliance A059102: A randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS7593-TPS7593.	1.6	0
11	Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7559-7559.	1.6	1
12	Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphomas.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7526-7526.	1.6	13
13	Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma. <i>Cancers</i> , 2022, 14, 2932.	3.7	5
14	CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received ≥ 1 line of systemic therapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS7588-TPS7588.	1.6	6
15	Results of the DIAL study (NCI 10089), a randomized phase 2 trial of varlilumab combined with nivolumab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA7564-LBA7564.	1.6	2
16	Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2022, 387, 310-320.	27.0	98
17	Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 1055-1065.	10.7	119
18	Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 831-839.	3.1	9

#	ARTICLE	IF	CITATIONS
19	A forgotten friend: CCNU as palliative monotherapy in relapsed Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 486-488.	1.3	1
20	CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder. <i>American Journal of Transplantation</i> , 2021, 21, 809-814.	4.7	44
21	Protect our children: Hodgkin lymphoma survivors. <i>Blood</i> , 2021, 137, 1433-1434.	1.4	2
22	Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. <i>Blood</i> , 2021, 138, 427-438.	1.4	109
23	Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 3339-3350.	7.0	26
24	Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Trials in Progress).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS7571-TPS7571.	1.6	2
25	Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7528-7528.	1.6	0
26	Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2408-2415.	1.3	2
27	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e410-e421.	4.6	83
28	Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021, 194, 690-700.	2.5	88
29	Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. <i>Leukemia</i> , 2021, 35, 2854-2861.	7.2	12
30	Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 3623-3632.	5.2	11
31	Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 4149-4155.	5.2	42
32	CD3xCD20 bispecific T-cell redirectors for relapsed or refractory B-cell lymphoma. <i>Lancet</i> , 2021, 398, 1109-1110.	13.7	2
33	Optimizing Second-Line Therapy for Hodgkin Lymphoma: A Work in Progress. <i>Journal of Clinical Oncology</i> , 2021, 39, 3097-3103.	1.6	4
34	Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. <i>American Journal of Surgical Pathology</i> , 2021, 45, 384-393.	3.7	10
35	Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	1
36	Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. <i>Lancet Haematology</i> , 2021, 8, e818-e827.	4.6	14

#	ARTICLE	IF	CITATIONS
37	Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	1
38	NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1218-1230.	4.9	98
39	Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6). <i>Blood</i> , 2021, 138, 2832-2832.	1.4	4
40	Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ECHELON-3, Trial in Progress). <i>Blood</i> , 2021, 138, 3564-3564.	1.4	1
41	The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma. <i>Blood</i> , 2021, 138, 135-135.	1.4	2
42	Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance. <i>Blood</i> , 2021, 138, 2417-2417.	1.4	3
43	Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study. <i>Blood</i> , 2021, 138, 127-127.	1.4	20
44	Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. <i>Blood</i> , 2021, 138, 639-639.	1.4	27
45	Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701. <i>Blood</i> , 2021, 138, 523-523.	1.4	14
46	Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study. <i>Blood</i> , 2021, 138, 3573-3573.	1.4	7
47	Prognostic Factors Other Than Age Drive the Risk of Disease Progression in Adults with Burkitt Lymphoma Treated with DA-EPOCH-R. <i>Blood</i> , 2021, 138, 453-453.	1.4	0
48	Novel Genetic Subgroups Inform on Shared Pathobiology within Adult and Pediatric Burkitt Lymphoma. <i>Blood</i> , 2021, 138, 806-806.	1.4	4
49	Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e808-e815.	4.6	55
50	Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. <i>Journal of Clinical Oncology</i> , 2020, 38, 3003-3011.	1.6	75
51	Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 3188-3197.	1.3	26
52	Hodgkin lymphoma. <i>Nature Reviews Disease Primers</i> , 2020, 6, 61.	30.5	103
53	A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2020, 136, 2401-2409.	1.4	92
54	A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2223-2228.	2.0	3

#	ARTICLE	IF	CITATIONS
55	Approaches to aggressive B-cell lymphomas in less fit patients. Hematology American Society of Hematology Education Program, 2020, 2020, 140-147.	2.5	1
56	Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. Leukemia and Lymphoma, 2020, 61, 2442-2447.	1.3	1
57	Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. Journal of Clinical Oncology, 2020, 38, 2519-2529.	1.6	93
58	Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. Lancet Haematology, the, 2020, 7, e490-e497.	4.6	14
59	Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. Blood, 2020, 135, 2224-2234.	1.4	62
60	Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Advances, 2020, 4, 858-867.	5.2	40
61	The justification of vincristine dose capping: tradition, traditionâ€¦   tradition!. Leukemia and Lymphoma, 2020, 61, 1007-1009.	1.3	1
62	Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: <scp>CALGB</scp>/Alliance 50403. American Journal of Hematology, 2020, 95, 583-593.	4.1	18
63	CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. Blood, 2020, 136, 2308-2318.	1.4	133
64	Treatment of Nodular Lymphocyte Hodgkin Lymphoma: The Goldilocks Principle. Journal of Clinical Oncology, 2020, 38, 662-668.	1.6	1
65	First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. Clinical Cancer Research, 2020, 26, 2524-2534.	7.0	40
66	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood, 2020, 135, 735-742.	1.4	86
67	Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial. Blood, 2020, 136, 42-44.	1.4	44
68	End of Treatment Peripheral Blood T-Cell Receptor Gene Rearrangement Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas. Blood, 2020, 136, 30-31.	1.4	2
69	Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood, 2020, 135, 2106-2109.	1.4	90
70	Phase I study of the Bcl-2 inhibitor venetoclax with DA-EPOCH-R as initial therapy for aggressive B-cell lymphomas.. Journal of Clinical Oncology, 2020, 38, 8003-8003.	1.6	4
71	Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials.. Journal of Clinical Oncology, 2020, 38, 8038-8038.	1.6	1
72	Local Review Versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial [Alliance]. Blood, 2020, 136, 50-50.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Patient-Specific Metabolism Assessed By Visceral Fat and Diabetes May Alter Prognosis in Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 30-31.	1.4	0
74	Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2020, 136, 3-4.	1.4	4
75	Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study. <i>Blood</i> , 2020, 136, 35-36.	1.4	23
76	Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. <i>Blood</i> , 2019, 134, 1238-1246.	1.4	86
77	Fifty Shades of GATA2 Mutation: A Case of Plasmablastic Lymphoma, Nontuberculous Mycobacterial Infection, and Myelodysplastic Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e532-e535.	0.4	4
78	Reply to T.M. Weis et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 2953-2953.	1.6	0
79	A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. <i>Blood</i> , 2019, 133, 1201-1204.	1.4	58
80	Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance). <i>Cancer</i> , 2019, 125, 3378-3389.	4.1	10
81	Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b/2 study. <i>Lancet Oncology</i> , The, 2019, 20, 998-1010.	10.7	101
82	Progressive multifocal leukoencephalopathy treated with nivolumab. <i>Journal of NeuroVirology</i> , 2019, 25, 284-287.	2.1	40
83	Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. <i>Journal of Clinical Oncology</i> , 2019, 37, 1790-1799.	1.6	266
84	Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. <i>Blood</i> , 2019, 133, 1762-1765.	1.4	35
85	To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1027-1030.	0.9	1
86	Parameters for Validating a Hospital Pneumatic Tube System. <i>Clinical Chemistry</i> , 2019, 65, 694-702.	3.2	20
87	ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study. <i>Haematologica</i> , 2019, 104, e65-e67.	3.5	11
88	The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials. <i>Cancer Medicine</i> , 2019, 8, 165-173.	2.8	27
89	Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 1718-1726.	7.0	26
90	Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 31-42.	10.7	1,467

#	ARTICLE	IF	CITATIONS
91	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 229-240.	13.7	517
92	Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study. <i>Blood</i> , 2019, 134, 238-238.	1.4	18
93	Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines. <i>Blood</i> , 2019, 134, 6-6.	1.4	152
94	PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001. <i>Blood</i> , 2019, 134, 349-349.	1.4	13
95	Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial. <i>Blood</i> , 2019, 134, 1524-1524.	1.4	3
96	The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672). <i>Blood</i> , 2019, 134, 1591-1591.	1.4	3
97	Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7518-7518.	1.6	20
98	The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A randomized phase 2 study of CDX-1127 (varlilumab) in combination with nivolumab in patients with relapsed or refractory aggressive B-cell lymphomas (NCI 10089/NCT03038672).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS7570-TPS7570.	1.6	2
99	Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1585-1585.	1.4	26
100	Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis. <i>Blood</i> , 2019, 134, 4027-4027.	1.4	0
101	Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas. <i>Blood</i> , 2019, 134, 1550-1550.	1.4	1
102	Composite Copy Number Variation in CDK4, CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as Revealed by Integrative Longitudinal scRNA-seq. <i>Blood</i> , 2019, 134, 1492-1492.	1.4	0
103	North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1553-1553.	1.4	0
104	Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. <i>Blood</i> , 2018, 131, 2120-2124.	1.4	56
105	Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients. <i>Blood</i> , 2018, 131, 1698-1703.	1.4	18
106	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 1396-1407.	27.0	1,443
107	SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 81-90.	0.4	3
108	Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study. <i>Leukemia and Lymphoma</i> , 2018, 59, 357-362.	1.3	7

#	ARTICLE	IF	CITATIONS
109	Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. <i>Blood</i> , 2018, 131, 182-190.	1.4	130
110	Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. <i>Cancer</i> , 2018, 124, 136-144.	4.1	47
111	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 331-344.	27.0	564
112	Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 1183-1194.	1.4	276
113	Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and Tj ETQq1 1 0.784314 rgBT /Overlo prospective, multicentre, single-arm phase 2 study. <i>Lancet Haematology</i> , the, 2018, 5, e609-e617.	4.6	152
114	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. <i>New England Journal of Medicine</i> , 2018, 379, 2517-2528.	27.0	706
115	Chimeric Antigen Receptor T-Cell Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1092-1106.	4.9	15
116	CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018, 379, 1711-1721.	27.0	796
117	Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. <i>New England Journal of Medicine</i> , 2018, 379, 934-947.	27.0	264
118	CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 601-611.	4.1	25
119	CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. <i>Blood</i> , 2018, 132, 1013-1021.	1.4	90
120	In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma. <i>Cancer Discovery</i> , 2018, 8, 1258-1269.	9.4	136
121	Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. <i>Haematologica</i> , 2018, 103, 1502-1510.	3.5	111
122	Abstract CT146: First-in-human phase I combination of the IL-15 receptor super agonist complex ALT-803 with a therapeutic (anti-CD20) monoclonal antibody (mAb) for patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL). <i>Cancer Research</i> , 2018, 78, CT146-CT146.	0.9	6
123	Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing). <i>Blood</i> , 2018, 132, 1635-1635.	1.4	9
124	The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas. <i>Blood</i> , 2018, 132, 997-997.	1.4	3
125	Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study. <i>Blood</i> , 2018, 132, 1647-1647.	1.4	10
126	Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach. <i>Blood</i> , 2018, 132, 929-929.	1.4	6



#	ARTICLE	IF	CITATIONS
127	Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis. <i>Blood</i> , 2018, 132, 2927-2927.	1.4	2
128	Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08). <i>Blood</i> , 2018, 132, 2964-2964.	1.4	4
129	Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. <i>Blood</i> , 2018, 132, 6-6.	1.4	18
130	Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma. <i>Blood</i> , 2018, 132, 2892-2892.	1.4	4
131	Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study. <i>Blood</i> , 2018, 132, 399-399.	1.4	48
132	A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data. <i>Blood</i> , 2018, 132, 1620-1620.	1.4	12
133	Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study. <i>Blood</i> , 2018, 132, 2904-2904.	1.4	4
134	Activity and tolerability of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7504-7504.	1.6	20
135	Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7541-7541.	1.6	4
136	Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas Including AITL and DLBCL: Phase I Results. <i>Blood</i> , 2018, 132, 2929-2929.	1.4	0
137	Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration. <i>Blood</i> , 2018, 132, 2878-2878.	1.4	0
138	Impact of Rituximab Infusion Reactions on Clinical Outcomes in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 4203-4203.	1.4	0
139	Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. <i>Molecular Therapy</i> , 2017, 25, 285-295.	8.2	498
140	Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2017, 178, 250-256.	2.5	30
141	Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. <i>Lancet Haematology</i> , 2017, 4, e176-e182.	4.6	77
142	Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw249.	6.3	31
143	Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. <i>Blood</i> , 2017, 129, 473-483.	1.4	147
144	Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted <sc>EPOCH</sc>. <i>British Journal of Haematology</i> , 2017, 179, 739-747.	2.5	101

#	ARTICLE	IF	CITATIONS
145	Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. <i>Blood</i> , 2017, 130, 2709-2717.	1.4	176
146	Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2199-2204.	2.0	7
147	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 2531-2544.	27.0	3,865
148	Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. <i>Leukemia and Lymphoma</i> , 2017, 58, 1607-1616.	1.3	46
149	Magnetic resonance image guided radiation therapy for primary splenic diffuse large B-cell lymphoma: A teaching case. <i>Practical Radiation Oncology</i> , 2017, 7, e23-e26.	2.1	2
150	Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 317-323.	2.5	7
151	A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 347-353.	0.4	23
152	Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3025-3025.	1.6	42
153	Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 7512-7512.	1.6	22
154	Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7537-7537.	1.6	2
155	Ironclad: A randomized phase III study of ibrutinib (Ibr) or no consolidation following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory activated-B-cell (ABC) subtype diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS7566-TPS7566.	1.6	1
156	Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma. <i>OncoTargets and Therapy</i> , 2016, 9, 2027.	2.0	3
157	Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. <i>American Journal of Hematology</i> , 2016, 91, 894-899.	4.1	15
158	Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. <i>Blood</i> , 2016, 128, 2510-2516.	1.4	56
159	Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. <i>Journal of Clinical Oncology</i> , 2016, 34, 1620-1625.	1.6	121
160	A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 875-882.	2.4	22
161	US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. <i>Journal of Clinical Oncology</i> , 2016, 34, 2020-2027.	1.6	239
162	Expression of TIA1 and PAX5 in Classical Hodgkin Lymphoma at Initial Diagnosis May Predict Clinical Outcome. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2016, 24, 383-391.	1.2	9

#	ARTICLE	IF	CITATIONS
163	Fine-Tuning the Treatment of Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2016, 374, 2490-2492.	27.0	9
164	Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. <i>Lancet Oncology</i> , 2016, 17, 200-211.	10.7	373
165	A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). <i>European Journal of Cancer</i> , 2016, 54, 11-17.	2.8	63
166	Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria. <i>Leukemia and Lymphoma</i> , 2016, 57, 1191-1193.	1.3	18
167	A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 1059-1066.	7.0	71
168	The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and <i>In Vivo</i> Clearance of B Cell Lymphomas. <i>Clinical Cancer Research</i> , 2016, 22, 596-608.	7.0	130
169	Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL). <i>Blood</i> , 2016, 128, 104-104.	1.4	14
170	Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 1105-1105.	1.4	17
171	A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma. <i>Blood</i> , 2016, 128, 150-150.	1.4	9
172	Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study. <i>Blood</i> , 2016, 128, 1853-1853.	1.4	5
173	Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 234-234.	1.4	36
174	Early Relapse of Follicular Lymphoma after Rituximab-Based Biologic Doublet Upfront Therapy Is Associated with Increased Risk of Death: A Combined Analysis from CALGB Studies 50402, 50701 and 50803 (Alliance). <i>Blood</i> , 2016, 128, 2953-2953.	1.4	3
175	SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial. <i>Blood</i> , 2016, 128, 2974-2974.	1.4	13
176	Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas. <i>Blood</i> , 2016, 128, 2993-2993.	1.4	5
177	Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2016, 128, 4144-4144.	1.4	9
178	Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303. <i>Blood</i> , 2016, 128, 469-469.	1.4	79
179	Toxicities and Related Outcomes of Elderly Patients (pts) (≥65 Years) with Hematologic Malignancies in the Contemporary Era (Alliance A151611). <i>Blood</i> , 2016, 128, 536-536.	1.4	1
180	PIK3IP1 Inhibition of PI3K in G1 Arrest Induced By CDK4 Inhibition Reprograms MCL for Ibrutinib Therapy. <i>Blood</i> , 2016, 128, 610-610.	1.4	2

#	ARTICLE	IF	CITATIONS
181	A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1. <i>Blood</i> , 2016, 128, 998-998.	1.4	26
182	Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1. <i>Blood</i> , 2016, 128, LBA-6-LBA-6.	1.4	30
183	Ongoing complete remissions (CR) in the phase 1 of ZUMA-1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7559-7559.	1.6	2
184	Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial. <i>Blood</i> , 2016, 128, 4403-4403.	1.4	0
185	Radiation for early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a double-edged sword?. <i>Leukemia and Lymphoma</i> , 2016, 57, 249-251.	1.3	0
186	Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. <i>Blood</i> , 2015, 125, 1394-1402.	1.4	242
187	Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). <i>Blood</i> , 2015, 126, 851-857.	1.4	161
188	Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma. <i>Blood</i> , 2015, 125, 3354-3355.	1.4	11
189	Biologic Agents in the Management of Hodgkin Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 587-596.	4.9	4
190	Gray zone lymphoma with features intermediate between classical <sc>H</sc>odgkin lymphoma and diffuse large <sc>B</sc>-cell lymphoma: <sc>C</sc>haracteristics, outcomes, and prognostication among a large multicenter cohort. <i>American Journal of Hematology</i> , 2015, 90, 778-783.	4.1	71
191	Evaluation of the International Prognostic Score (IPS&#7) and a Simpler Prognostic Score (IPS&#3) for advanced Hodgkin lymphoma in the modern era. <i>British Journal of Haematology</i> , 2015, 171, 530-538.	2.5	54
192	Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. <i>Leukemia and Lymphoma</i> , 2015, 56, 2569-2578.	1.3	36
193	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 2425-2437.	27.0	1,261
194	Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. <i>Journal of Clinical Oncology</i> , 2015, 33, 2399-2404.	1.6	97
195	Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. <i>Journal of Geriatric Oncology</i> , 2015, 6, 211-218.	1.0	47
196	Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1936-1942.	1.6	33
197	Blinatumomab for the treatment of B-cell lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 715-724.	4.1	30
198	A Young Woman With Blurred Vision and Distal Paresthesias. <i>JAMA Neurology</i> , 2015, 72, 1519.	9.0	0

#	ARTICLE	IF	CITATIONS
199	Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies. <i>Leukemia and Lymphoma</i> , 2015, 56, 1151-1153.	1.3	11
200	Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 3635-3640.	1.6	163
201	Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). <i>Leukemia and Lymphoma</i> , 2015, 56, 958-964.	1.3	36
202	Frontline Treatment of CD30+ Peripheral T-Cell Lymphomas with Brentuximab Vedotin in Combination with CHP: 3-Year Durability and Survival Follow-up. <i>Blood</i> , 2015, 126, 1537-1537.	1.4	5
203	Polatumumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-Escalation. <i>Blood</i> , 2015, 126, 2726-2726.	1.4	6
204	Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance). <i>Blood</i> , 2015, 126, 2741-2741.	1.4	3
205	Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab. <i>Blood</i> , 2015, 126, 2936-2936.	1.4	2
206	Interfollicular CD10 Expression and Follicular PD1 Tumor-Infiltrating Lymphocytes As Biologic Risk Factors in Patients with Previously Untreated Follicular Lymphoma Receiving Rituximab-Based Biologic Therapy: An Alliance Correlative Science Study (CALGB 50901, 50402, 50701, 50803, 50401). <i>Blood</i> , 2015, 126, 334-334.	1.4	2
207	Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403. <i>Blood</i> , 2015, 126, 337-337.	1.4	23
208	Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R. <i>Blood</i> , 2015, 126, 342-342.	1.4	14
209	A Phase I Trial of Brentuximab Vedotin in Combination with Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 3988-3988.	1.4	5
210	Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2015, 126, 3991-3991.	1.4	9
211	Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM). <i>Blood</i> , 2015, 126, 495-495.	1.4	2
212	Recurrent Somatic Genomic Alterations in Follicular NHL (FL) Revealed By Exome and Custom-Capture Next Generation Sequencing. <i>Blood</i> , 2015, 126, 574-574.	1.4	2
213	Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604). <i>Blood</i> , 2015, 126, 578-578.	1.4	21
214	Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study. <i>Blood</i> , 2015, 126, 814-814.	1.4	4
215	Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8506-8506.	1.6	5
216	Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 3961-3961.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG) Tj ETQq1 1 0.784314 rgBTi/Overlo		
218	Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN. <i>Blood</i> , 2015, 126, 1539-1539.	1.4	0
219	Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2015, 126, 2938-2938.	1.4	1
220	Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2015, 126, 2730-2730.	1.4	2
221	High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2014, 55, 1345-1349.	1.3	67
222	CD163 Immunohistochemistry Is Superior to CD68 in Predicting Outcome in Classical Hodgkin Lymphoma. <i>American Journal of Clinical Pathology</i> , 2014, 141, 381-387.	0.7	51
223	Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission. <i>Cancer</i> , 2014, 120, 2122-2129.	4.1	29
224	Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers. <i>Therapeutic Advances in Hematology</i> , 2014, 5, 3-12.	2.5	17
225	A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. <i>Journal of Hematology and Oncology</i> , 2014, 7, 44.	17.0	76
226	Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30 <sup>+</sup> Peripheral T-Cell Lymphomas: Results of a Phase I Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 3137-3143.	1.6	153
227	Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. <i>British Journal of Haematology</i> , 2014, 165, 510-518.	2.5	34
228	Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 1797-1803.	1.6	75
229	Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte-â€“Predominant Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 912-918.	1.6	96
230	Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. <i>Journal of Hematology and Oncology</i> , 2014, 7, 24.	17.0	144
231	Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. <i>Leukemia and Lymphoma</i> , 2014, 55, 2328-2334.	1.3	48
232	Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. <i>Blood</i> , 2014, 123, 3095-3100.	1.4	280
233	Brentuximab Vedotin in Combination with RCHOP As Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study. <i>Blood</i> , 2014, 124, 1745-1745.	1.4	4
234	Unexpected and Serious Toxicity Observed with Combined Idelalisib, Lenalidomide and Rituximab in Relapsed/Refractory B Cell Lymphomas: Alliance A051201 and A051202. <i>Blood</i> , 2014, 124, 3091-3091.	1.4	28

#	ARTICLE	IF	CITATIONS
235	Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2014, 124, 3095-3095.	1.4	14
236	A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL). <i>Blood</i> , 2014, 124, 3099-3099.	1.4	3
237	Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 395-395.	1.4	40
238	Brentuximab Vedotin Monotherapy in DLBCL Patients with Undetectable CD30: Preliminary Results from a Phase 2 Study. <i>Blood</i> , 2014, 124, 629-629.	1.4	5
239	Ibrutinib Monotherapy in Relapsed/Refractory Follicular Lymphoma (FL): Preliminary Results of a Phase 2 Consortium (P2C) Trial. <i>Blood</i> , 2014, 124, 800-800.	1.4	30
240	Safety Results from the United States Cohort of the Ibrutinib Early Access Treatment Protocol (EAP): Tj ETQqO O O rgBT /Overlock 10 Tf 5	1.4	0
241	Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome. <i>Blood</i> , 2014, 124, 1703-1703.	1.4	0
242	Commentary. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 18-23.	0.3	0
243	Highlights in lymphoma from the 2013 American Society of Hematology Annual Meeting and Exposition: commentary. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12 Suppl 6, 18-23.	0.3	1
244	Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 692-700.	1.6	176
245	Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). <i>Journal of Clinical Oncology</i> , 2013, 31, 684-691.	1.6	256
246	The efficacy and tolerability of adriamycin, bleomycin, vinblastine and dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. <i>British Journal of Haematology</i> , 2013, 161, 76-86.	2.5	111
247	The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). <i>Leukemia and Lymphoma</i> , 2013, 54, 1405-1410.	1.3	27
248	Anaplastic Large-Cell Lymphoma With Aberrant Expression of Multiple Cytokeratins Masquerading As Metastatic Carcinoma of Unknown Primary. <i>Journal of Clinical Oncology</i> , 2013, 31, e443-e445.	1.6	19
249	Assessment of Cellular Proliferation in Tumors by PET Using <sup>18</sup> F-ISO-1. <i>Journal of Nuclear Medicine</i> , 2013, 54, 350-357.	5.0	76
250	Lymphoma Occurring During Pregnancy: Antenatal Therapy, Complications, and Maternal Survival in a Multicenter Analysis. <i>Journal of Clinical Oncology</i> , 2013, 31, 4132-4139.	1.6	93
251	Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. <i>Blood</i> , 2013, 121, 3547-3553.	1.4	117
252	Limited-Stage Hodgkin Lymphoma: Optimal Chemotherapy and the Role of Radiotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 374-380.	3.8	2

#	ARTICLE	IF	CITATIONS
253	Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma. Blood, 2013, 122, 1809-1809.	1.4	24
254	The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience. Blood, 2013, 122, 3060-3060.	1.4	5
255	Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496. Blood, 2013, 122, 4277-4277.	1.4	3
256	Lack Of Clinical Benefit For Routine Surveillance Imaging For Diffuse Large B-Cell Lymphoma In First Complete Remission. Blood, 2013, 122, 4303-4303.	1.4	2
257	Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas. Blood, 2013, 122, 4386-4386.	1.4	6
258	A Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results In Patients With DLBCL and Other B-Cell Lymphomas. Blood, 2013, 122, 848-848.	1.4	33
259	Limited-Stage Hodgkin Lymphoma: Optimal Chemotherapy and the Role of Radiotherapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, 374-380.	3.8	6
260	Lymphoma Surveillance Counterpoint: USA. , 2013, , 461-466.		0
261	Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients. Blood, 2013, 122, 1785-1785.	1.4	0
262	Gray Zone Lymphoma (GZL) With Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective Multicenter Analysis Of Clinical Characteristics, Treatment, Outcomes, and Prognosis In The Current Era. Blood, 2013, 122, 847-847.	1.4	2
263	Treatment of nodular lymphocyte-predominant Hodgkin lymphoma-"do no harm". Clinical Advances in Hematology and Oncology, 2013, 11, 385-7.	0.3	1
264	Brentuximab Vedotin in Transplant-Naïve Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies. Oncologist, 2012, 17, 1073-1080.	3.7	42
265	Increased Body Mass Index Is Associated With Improved Survival in United States Veterans With Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2012, 30, 3217-3222.	1.6	78
266	Brentuximab Vedotin and Crizotinib in Anaplastic Large-Cell Lymphoma. Cancer Journal (Sudbury, Mass) Tj ETQq0 0,0 rgBT /Overlock 10	2.0	41
267	Interim [ <sup>18</sup> F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?. Leukemia and Lymphoma, 2012, 53, 2143-2150.	1.3	54
268	Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood, 2012, 120, 3280-3287.	1.4	188
269	Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. Journal of Clinical Oncology, 2012, 30, 2190-2196.	1.6	890
270	Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. Journal of Clinical Oncology, 2012, 30, 2183-2189.	1.6	1,332



#	ARTICLE	IF	CITATIONS
271	A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2012, 18, 248-255.	7.0	204
272	Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 506-507.	1.3	15
273	Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. <i>Leukemia and Lymphoma</i> , 2012, 53, 2283-2286.	1.3	44
274	Solid, Low-Attenuation Splenic Lesions on Computed Tomography in Patients With Indolent Lymphoma Often Signal Transformation: A Series of Ten Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 452-454.	0.4	0
275	Where Does Brentuximab Vedotin Fit into the Management of Patients with Hodgkin Lymphoma?. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 179-185.	2.3	8
276	A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. <i>Cancer</i> , 2012, 118, 3128-3134.	4.1	95
277	A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 1623-1623.	1.4	7
278	A Phase I Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL). <i>Blood</i> , 2012, 120, 1644-1644.	1.4	5
279	Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.. <i>Blood</i> , 2012, 120, 2745-2745.	1.4	6
280	A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results.. <i>Blood</i> , 2012, 120, 2746-2746.	1.4	9
281	Retrospective Analysis of the Safety and Efficacy of Brentuximab Vedotin in Patients Aged 60 Years or Older with Relapsed or Refractory CD30+ Hematologic Malignancies. <i>Blood</i> , 2012, 120, 3687-3687.	1.4	2
282	A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2012, 120, 55-55.	1.4	10
283	Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas. <i>Blood</i> , 2012, 120, 60-60.	1.4	32
284	Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years. <i>Blood</i> , 2012, 120, 4779-4779.	1.4	0
285	Defining the Malignant Epigenome in Non-Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 524-524.	1.4	1
286	Advances in LLM: Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2012, 10, 468-71.	0.3	0
287	A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. <i>Leukemia and Lymphoma</i> , 2011, 52, 587-596.	1.3	26
288	Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1646-1652.	2.0	92

#	ARTICLE	IF	CITATIONS
289	Composite diffuse large B-cell lymphoma and precursor B lymphoblastic lymphoma presenting as a double-hit lymphoma with MYC and BCL2 translocation. <i>Journal of Clinical Pathology</i> , 2011, 64, 1032-1034.	2.0	7
290	Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. <i>Blood</i> , 2011, 117, 5314-5320.	1.4	56
291	A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. <i>Blood</i> , 2011, 118, 5119-5125.	1.4	181
292	18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation. <i>Journal of Nuclear Medicine</i> , 2011, 52, 386-392.	5.0	151
293	Brentuximab vedotin for the treatment of CD30 <sup>+</sup> lymphomas. <i>Immunotherapy</i> , 2011, 3, 475-485.	2.0	37
294	Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496. <i>Blood</i> , 2011, 118, 1603-1603.	1.4	3
295	Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone?. <i>Blood</i> , 2011, 118, 3644-3644.	1.4	3
296	Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL). <i>Blood</i> , 2011, 118, 3711-3711.	1.4	8
297	A Gene Expression Signature in Diagnostic Formalin Fixed Paraffin Embedded Tissue Predicts Overall Survival in Locally Advanced and Advanced Stage Classical Hodgkin Lymphoma – a Correlative Study From the E2496 Intergroup Trial. <i>Blood</i> , 2011, 118, 430-430.	1.4	1
298	Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update. <i>Blood</i> , 2011, 118, 443-443.	1.4	11
299	Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis. <i>Blood</i> , 2011, 118, 94-94.	1.4	4
300	Role of Routine Imaging in Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 575-584.	4.9	18
301	Frontline Therapy of Nodular Lymphocyte Predominant Hodgkin Lymphoma with Rituximab: The Stanford University Experience. <i>Blood</i> , 2011, 118, 2686-2686.	1.4	3
302	Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. <i>Cancer</i> , 2010, 116, 106-114.	4.1	217
303	The Present: Optimizing Therapy – Too Much or Too Little?. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 108-114.	2.5	3
304	Anti-CD30 Antibodies for Hodgkin Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2010, 5, 140-147.	2.3	47
305	Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. <i>New England Journal of Medicine</i> , 2010, 363, 1812-1821.	27.0	1,266
306	Pralatrexate Is Effective In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with Prior Ifosfamide, Carboplatin, and Etoposide (ICE)-Based Regimens. <i>Blood</i> , 2010, 116, 1753-1753.	1.4	3

#	ARTICLE	IF	CITATIONS
307	Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study.. Blood, 2010, 116, 2800-2800.	1.4	12
308	A Randomized Phase III Trial of ABVD Vs. Stanford V +/â” Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). Blood, 2010, 116, 415-415.	1.4	18
309	Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496. Blood, 2010, 116, 416-416.	1.4	8
310	Pralatrexate Reverses the Trend to Progressive Resistance to Successive Systemic Treatment Regimens In Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL). Blood, 2010, 116, 4881-4881.	1.4	1
311	Pralatrexate Is Effective as Second-Line Treatment Following Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) Failure In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL). Blood, 2010, 116, 4882-4882.	1.4	6
312	Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. Blood, 2010, 116, 961-961.	1.4	13
313	Clonal Ig DNA Detection In Plasma From Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2010, 116, 3127-3127.	1.4	0
314	Forodesine, a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Shows Clinical Activity In a Phase 2 Trial In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL) â” Interim Analysis. Blood, 2010, 116, 1397-1397.	1.4	4
315	Drug development for recurrent and refractory classical Hodgkin lymphoma. Leukemia and Lymphoma, 2009, 50, 529-540.	1.3	13
316	Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909. Journal of Clinical Oncology, 2009, 27, 6101-6108.	1.6	182
317	Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551. Cancer Chemotherapy and Pharmacology, 2009, 63, 793-798.	2.3	6
318	A Phase II study of SGNâ”30 (antiâ”CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. British Journal of Haematology, 2009, 146, 171-179.	2.5	230
319	Protein Losing Enteropathy Associated With Follicular Lymphoma of the Small Bowel. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 222-223.	1.3	5
320	Phase I Analysis of the Safety and Pharmacodynamics of the Novel Broad Spectrum Histone Deacetylase Inhibitor (HDACi) PCI-24781 in Relapsed and Refractory Lymphoma.. Blood, 2009, 114, 2726-2726.	1.4	6
321	The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study.. Blood, 2009, 114, 2731-2731.	1.4	22
322	Prognostic Significance of PET Imaging in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation.. Blood, 2009, 114, 3417-3417.	1.4	1
323	A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.. Blood, 2009, 114, 3693-3693.	1.4	12
324	A Phase 1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine: Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell Lymphoma.. Blood, 2009, 114, 586-586.	1.4	4

#	ARTICLE	IF	CITATIONS
325	Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. <i>British Journal of Haematology</i> , 2008, 140, 313-319.	2.5	26
326	High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - A CALGB 59804 correlative study. <i>Leukemia and Lymphoma</i> , 2008, 49, 1202-1205.	1.3	10
327	A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. <i>Blood</i> , 2008, 111, 1848-1854.	1.4	189
328	Modern treatment of Hodgkin lymphoma. <i>Current Opinion in Hematology</i> , 2008, 15, 408-414.	2.5	27
329	Multiple Complete Responses in a Phase 1 Dose-Escalation Study of the Antibody-Drug Conjugate SGN-35 in Patients with Relapsed or Refractory CD30-Positive Lymphomas. <i>Blood</i> , 2008, 112, 1006-1006.	1.4	31
330	Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502. <i>Blood</i> , 2008, 112, 232-232.	1.4	7
331	A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results. <i>Blood</i> , 2008, 112, 2595-2595.	1.4	8
332	Poor Predictive Value of FDG-PET/CT Performed after 2 Cycles of R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLCL). <i>Blood</i> , 2008, 112, 371-371.	1.4	13
333	Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results. <i>Blood</i> , 2008, 112, 1460-1460.	1.4	0
334	Salvage regimens for Hodgkin lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 517-24.	0.3	6
335	Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206. <i>Leukemia and Lymphoma</i> , 2007, 48, 1313-1319.	1.3	64
336	Therapy of Relapsed Hodgkin Lymphoma. <i>Blood Reviews</i> , 2007, 21, 233-243.	5.7	15
337	Bendamustine Is Safe and Effective in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2007, 110, 1351-1351.	1.4	6
338	Results of a Prospective Phase II Trial of Limited and Extended Rituximab Treatment in Nodular Lymphocyte Predominant Hodgkin's Disease (NLPHD). <i>Blood</i> , 2007, 110, 644-644.	1.4	17
339	Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: Results of CALGB 59906. <i>Leukemia and Lymphoma</i> , 2006, 47, 1511-1517.	1.3	9
340	Management of Advanced Stage Hodgkin's Lymphoma. , 2006, 131, 333-352.		2
341	SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL). <i>Blood</i> , 2006, 108, 2718-2718.	1.4	11
342	A Phase I Open Label Dose Escalation Study To Evaluate MEDI-507 in Patients with CD2-Positive T-Cell Lymphoma/Leukemia. <i>Blood</i> , 2006, 108, 2727-2727.	1.4	10

#	ARTICLE	IF	CITATIONS
343	Immuno-Chemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909.. Blood, 2006, 108, 2737-2737.	1.4	3
344	Banoxantrone (AQ4N), a Tissue Targeted Prodrug: Results of a Phase 1 Study in Lymphomas.. Blood, 2006, 108, 2429-2429.	1.4	3
345	Therapies for Relapsed Hodgkin Lymphoma: Transplant and Non-Transplant Approaches Including Immunotherapy. Hematology American Society of Hematology Education Program, 2005, 2005, 245-251.	2.5	12
346	90Yttrium-90-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma. Expert Opinion on Biological Therapy, 2004, 4, 1323-1331.	3.1	0
347	Phase II Study of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent Hodgkin's Disease.. Blood, 2004, 104, 2635-2635.	1.4	39
348	A Phase II Study of Xcellerated T Cells, in Patients with Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma (NHL).. Blood, 2004, 104, 4640-4640.	1.4	0
349	Antibodies for the treatment of diffuse large cell lymphoma. Seminars in Oncology, 2003, 30, 448-456.	2.2	15
350	Interdigitating dendritic reticulum cell tumor of lymph nodes: Case report with differential diagnostic considerations. Diagnostic Cytopathology, 2003, 28, 278-281.	1.0	23
351	Radiation Dosimetry Results From a Phase II Trial of Ibritumomab Tiuxetan (Zevalin, ) Radioimmunotherapy for Patients With Non-Hodgkin's Lymphoma and Mild Thrombocytopenia. Cancer Biotherapy and Radiopharmaceuticals, 2003, 18, 165-178.	1.0	30
352	Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood, 2003, 101, 4285-4289.	1.4	191
353	Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood, 2002, 99, 4336-4342.	1.4	257
354	Randomized Controlled Trial of Yttrium-90-Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2002, 20, 2453-2463.	1.6	1,069
355	Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin's Disease: Mature Results of a Prospective Clinical Trial. Journal of Clinical Oncology, 2002, 20, 630-637.	1.6	261
356	Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies. Cancer, 2002, 95, 2223-2229.	4.1	14
357	Cyclin D1 as an Aid in the Diagnosis of Mantle Cell Lymphoma in Skin Biopsies: A Case Report. American Journal of Dermatopathology, 2001, 23, 470-476.	0.6	25
358	Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin, radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Critical Reviews in Oncology/Hematology, 2001, 39, 181-194.	4.4	161
359	Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma. Cancer, 2001, 92, 207-217.	4.1	31
360	Hodgkin's disease: Prognostic factors and short-course regimens. Current Oncology Reports, 2000, 2, 163-171.	4.0	2

#	ARTICLE	IF	CITATIONS
361	Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin's Disease: Eastern Cooperative Oncology Group Pilot Study E1492. <i>Journal of Clinical Oncology</i> , 2000, 18, 972-972.	1.6	101
362	Treatment advances in non-Hodgkin's lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 451-465.	1.8	4
363	Intravascular lymphoma associated with endocrine dysfunction: a report of four cases and a review of the literature. <i>American Journal of Medicine</i> , 1999, 107, 169-176.	1.5	27
364	Bone marrow staging in patients with non-hodgkin's lymphoma. , 1998, 82, 1154-1159.		35
365	Splenic Pathology in Myelodysplasia. <i>American Journal of Surgical Pathology</i> , 1998, 22, 1255-1266.	3.7	48
366	Treatment of aggressive histology lymphoma. <i>Current Opinion in Oncology</i> , 1997, 9, 413-419.	2.4	2
367	Assessment of knowledge about cancer pain management by physicians in training. <i>Journal of Pain and Symptom Management</i> , 1997, 14, 21-28.	1.2	53
368	MACOP-B ± radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford Results According to Prognostic Indices. <i>Cancer</i> , 1993, 71, 4034-4042.	4.1	9
369	Serum Markers in Germ Cell Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 1991, 5, 1245-1260.	2.2	31